"I wish RVX was sold before Topline was announced when all indications pointed to a sure hit."

I personally see apabetalone and Resverlogix de-risked since top-line. It was far from a "sure hit" pre-top-line. BETonMACE was the biggest validation of apabetalone yet. 18-20% RRR for 3-point MACE, just missing stat significance. That is MUCH stronger validation than the post-hoc 5-point MACE observations. And the safety profile seems great! We already know the MACE reduction was out of this world (~50% RRR) in the CKD sub-group. IF apabetalone also improves eGFR/renal function (still waiting on this data), then apabetalone has HUGE potential for diabetic kidney disease patients. Add in cognitive function improvement in this population too (big overlap between CKD and cognition sub-study patients), then this is blockbuster material. All just my opinion.

BDAZ